CN109790164B - 作为胆碱激酶抑制剂的嘌呤和3-去氮杂嘌呤类似物 - Google Patents

作为胆碱激酶抑制剂的嘌呤和3-去氮杂嘌呤类似物 Download PDF

Info

Publication number
CN109790164B
CN109790164B CN201780058594.3A CN201780058594A CN109790164B CN 109790164 B CN109790164 B CN 109790164B CN 201780058594 A CN201780058594 A CN 201780058594A CN 109790164 B CN109790164 B CN 109790164B
Authority
CN
China
Prior art keywords
compound
amino
purin
cis
cyclohexanecarboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780058594.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN109790164A (zh
Inventor
E·卡萨莱
艾米丽亚娜·科尔蒂
P·戈奇
M·内斯
S·C·奥兰纽斯
F·夸尔蒂耶里
费德里科·里卡尔迪西尔托里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nerviano Medical Sciences SRL
Original Assignee
Nerviano Medical Sciences SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences SRL filed Critical Nerviano Medical Sciences SRL
Publication of CN109790164A publication Critical patent/CN109790164A/zh
Application granted granted Critical
Publication of CN109790164B publication Critical patent/CN109790164B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780058594.3A 2016-07-25 2017-07-19 作为胆碱激酶抑制剂的嘌呤和3-去氮杂嘌呤类似物 Active CN109790164B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16181105 2016-07-25
EP16181105.4 2016-07-25
PCT/EP2017/068255 WO2018019681A1 (en) 2016-07-25 2017-07-19 Purine and 3-deazapurine analogues as choline kinase inhibitors

Publications (2)

Publication Number Publication Date
CN109790164A CN109790164A (zh) 2019-05-21
CN109790164B true CN109790164B (zh) 2022-01-25

Family

ID=56550132

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780058594.3A Active CN109790164B (zh) 2016-07-25 2017-07-19 作为胆碱激酶抑制剂的嘌呤和3-去氮杂嘌呤类似物

Country Status (6)

Country Link
US (1) US10683292B2 (enExample)
EP (1) EP3487857B1 (enExample)
JP (1) JP6920411B2 (enExample)
CN (1) CN109790164B (enExample)
ES (1) ES2899114T3 (enExample)
WO (1) WO2018019681A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102445887B1 (ko) 2016-04-21 2022-09-21 아스트로사이트 파마슈티컬스, 인코포레이티드 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법
CN110183442A (zh) * 2019-06-06 2019-08-30 无锡合全药业有限公司 一种1 -(乙氧羰基)咪唑并[1, 5]吡啶-6-羧酸的合成方法
EP4329773A4 (en) * 2021-04-28 2025-06-04 Astrocyte Pharmaceuticals, Inc. PURINE NUCLEOSIDES, THEIR INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION
JP2023074248A (ja) 2021-11-17 2023-05-29 信越化学工業株式会社 有機膜形成用組成物、パターン形成方法並びに有機膜形成用化合物及び重合体
WO2024044751A2 (en) * 2022-08-26 2024-02-29 Wake Forest University Health Sciences Peroxiredoxin 3 inhibitors and methods of use for treating cancer
CN115403593B (zh) * 2022-09-22 2024-02-02 河南师范大学 一种环加成合成手性嘌呤[3,2-c]并噁唑化合物的方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009116074A2 (en) * 2008-02-13 2009-09-24 Cadila Healthcare Limited Substituted benzimidazoles as cannabinoid modulator
CN103687964A (zh) * 2011-06-20 2014-03-26 特拉斯雷神诺癌症医药有限公司 用于预测患有癌症之对象对化疗之临床响应的方法
WO2014151761A1 (en) * 2013-03-15 2014-09-25 Ariad Pharmaceuticals, Inc. Novel choline kinase inhibitors
WO2014165216A1 (en) * 2013-03-12 2014-10-09 The Trustees Of The University Of Pennsylvania Diagnosing and treating cancer
WO2015151006A1 (en) * 2014-03-29 2015-10-08 Lupin Limited Substituted purine compounds as btk inhibitors
CN109311882A (zh) * 2016-05-04 2019-02-05 Bci制药公司 作为蛋白激酶抑制剂的腺嘌呤衍生物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3687030T2 (de) * 1985-03-15 1993-03-11 Eugene Stirchak Stereoregulare polynukleotiden bindende polymere.
DE10139730A1 (de) * 2001-08-13 2003-02-27 Nanogen Recognomics Gmbh Verfahren zur Herstellung CNA
EP1663193B1 (en) * 2003-09-12 2012-04-04 Merck Serono SA Sulfonamide derivatives for the treatment of diabetes
ES2237332B1 (es) 2004-01-14 2006-11-01 Consejo Sup. Investig. Cientificas Derivados de piridinio y quinolinio.
ES2277568B1 (es) 2005-12-30 2008-04-01 Consejo Superior De Investigaciones Cientificas Derivados de triterpenoquinona y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.
EP2632898A4 (en) * 2010-10-29 2014-04-02 Biogen Idec Inc HETEROCYCLIC TYROSINE KINASE HEMMER
MX2014003497A (es) 2011-09-22 2014-07-22 Vertex Pharma Compuestos utiles como inhibidores de colina cinasa.
MX2014003491A (es) 2011-09-22 2014-07-22 Vertex Pharma Compuestos utiles como inhibidores de colina cinasa.
DK2880025T3 (en) * 2012-08-02 2019-03-18 Nerviano Medical Sciences Srl SUBSTITUTED PYROLES ACTIVE AS KINase INHIBITORS
ES2482290B1 (es) 2014-06-05 2015-05-19 Universidad De Granada Inhibidores polares simétricos de colina cinasa con actividad antitumoral
SI3303334T1 (sl) * 2015-06-03 2021-09-30 Principia Biopharma Inc. Zaviralci tirozin kinaz

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009116074A2 (en) * 2008-02-13 2009-09-24 Cadila Healthcare Limited Substituted benzimidazoles as cannabinoid modulator
CN103687964A (zh) * 2011-06-20 2014-03-26 特拉斯雷神诺癌症医药有限公司 用于预测患有癌症之对象对化疗之临床响应的方法
WO2014165216A1 (en) * 2013-03-12 2014-10-09 The Trustees Of The University Of Pennsylvania Diagnosing and treating cancer
WO2014151761A1 (en) * 2013-03-15 2014-09-25 Ariad Pharmaceuticals, Inc. Novel choline kinase inhibitors
WO2015151006A1 (en) * 2014-03-29 2015-10-08 Lupin Limited Substituted purine compounds as btk inhibitors
CN109311882A (zh) * 2016-05-04 2019-02-05 Bci制药公司 作为蛋白激酶抑制剂的腺嘌呤衍生物

Also Published As

Publication number Publication date
US10683292B2 (en) 2020-06-16
CN109790164A (zh) 2019-05-21
ES2899114T3 (es) 2022-03-10
EP3487857B1 (en) 2021-09-01
WO2018019681A1 (en) 2018-02-01
JP6920411B2 (ja) 2021-08-18
US20190225615A1 (en) 2019-07-25
EP3487857A1 (en) 2019-05-29
JP2019522018A (ja) 2019-08-08

Similar Documents

Publication Publication Date Title
CN109790164B (zh) 作为胆碱激酶抑制剂的嘌呤和3-去氮杂嘌呤类似物
EP3080100B1 (en) Inhibitors of lysine specific demethylase-1
EP3472165B1 (en) N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors
EP2997030B1 (en) Pyrrolo[2,3-d]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
ES2616812T3 (es) Compuestos piridilo sustituidos con heterociclo bicíclico útiles como moduladores de quinasa
KR102475498B1 (ko) 리신 특이적 데메틸라아제-1의 억제제
AU2011344270A1 (en) Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
JPWO2005095419A1 (ja) チアゾロピリミジン誘導体
EP2721016A1 (en) Trpv4 antagonists
CN102015705A (zh) 稠合的杂环衍生物及其用途
KR101660863B1 (ko) IKKε 및 TBK1 억제제로서의 7-아자인돌 또는 4,7-다이아자인돌 유도체 및 이를 포함하는 약학적 조성물
WO2018066718A1 (en) Therapeutic compounds
TWI762534B (zh) 作為ＰＩ３Ｋδ抑制劑的咪唑並[1,5-A]吡衍生物
TW202406908A (zh) 新型prmt5抑制劑及其應用
HK40006205A (en) Purine and 3-deazapurine analogues as choline kinase inhibitors
CN117177975A (zh) 嘧啶并[5,4,d]嘧啶化合物、包含其的组合物及其用途
HK40006205B (zh) 作为胆碱激酶抑制剂的嘌呤和3-去氮杂嘌呤类似物
TW202132295A (zh) Gem二取代之雜環化合物及其作為idh抑制劑之用途
HK40002986A (en) Pyridopyrimdinone cdk2/4/6 inhibitors
HK1230202A1 (en) Inhibitors of lysine specific demethylase-1
HK1230202B (en) Inhibitors of lysine specific demethylase-1

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Milano, Italy

Applicant after: NERVIANO MEDICAL SCIENCES S.R.L.

Address before: Milano, Italy

Applicant before: NERVIANO MEDICAL SCIENCES S.R.L.

CB02 Change of applicant information
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40006205

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant